Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study

Tasuku Hashimoto,1,2 Daiji Sakurai,1 Yasunori Oda,1 Tadashi Hasegawa,3 Nobuhisa Kanahara,4 Tsuyoshi Sasaki,3 Hideki Komatsu,3,5 Junpei Takahashi,1,5 Takahiro Oiwa,6 Yoshimoto Sekine,4,5 Hiroyuki Watanabe,1 Masaomi Iyo1,3 1Department of Psychiatry, Chiba University Graduate School of Medicine, 2Sode...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hashimoto T, Sakurai D, Oda Y, Hasegawa T, Kanahara N, Sasaki T, Komatsu H, Takahashi J, Oiwa T, Sekine Y, Watanabe H, Iyo M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	major depressive disorder milnacipran biomarkers adverse effects cytokines Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4f49e3d6e16448a5b0101b6cdf3d5734
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f49e3d6e16448a5b0101b6cdf3d5734
record_format	dspace
spelling	oai:doaj.org-article:4f49e3d6e16448a5b0101b6cdf3d57342021-12-02T00:05:11ZMilnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study1178-2021https://doaj.org/article/4f49e3d6e16448a5b0101b6cdf3d57342015-12-01T00:00:00Zhttps://www.dovepress.com/milnacipran-treatment-and-potential-biomarkers-in-depressed-patients-f-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Tasuku Hashimoto,1,2 Daiji Sakurai,1 Yasunori Oda,1 Tadashi Hasegawa,3 Nobuhisa Kanahara,4 Tsuyoshi Sasaki,3 Hideki Komatsu,3,5 Junpei Takahashi,1,5 Takahiro Oiwa,6 Yoshimoto Sekine,4,5 Hiroyuki Watanabe,1 Masaomi Iyo1,3 1Department of Psychiatry, Chiba University Graduate School of Medicine, 2Sodegaura Satsukidai Hospital, 3Department of Psychiatry, Chiba University Hospital, 4Division of Medical Treatment and Rehabilitation, Centre for Forensic Mental Health, Chiba University, 5Choshi Kokoro Clinic, 6Mobara Shinkeika Hospital, Chiba, Japan Background: We assessed the effect of switching patients with major depressive disorder to milnacipran following an initial selective serotonin reuptake inhibitor treatment failure, and explored potential biomarkers in their blood.Methods: We conducted a prospective, open-label, 24-week trial. Depression was assessed with the 17-item Hamilton Depression Rating Scale. Patients showing a ≥50% reduction in Hamilton Depression Rating Scale scores from baseline to final visit were considered responders. Regarding adverse effects (AEs), moderate-to-severe AEs were specifically identified as effects that required any medical treatment or that induced treatment withdrawals. We also measured blood levels of various molecules including inflammatory cytokines.Results: Of the 30 participants who enrolled, 17 completed this study. The responder rate was 30% (n=10). Baseline serum levels of interleukin-6 (Z=-2.155; P=0.031) and interleukin-8 (Z=-2.616; P=0.009) were significantly higher when moderate-to-severe AEs were present (n=13 patients with moderate-to-severe AEs). Serum levels of macrophage inflammatory protein-1β showed a significant continuous decrease from the baseline level (Friedman’s test: χ2=23.9, df=4, P<0.001) only in non-responders.Conclusion: These results demonstrate that serum levels of interleukin-6, interleukin-8, and macrophage inflammatory protein-1β as potential blood biomarkers could be utilized to identify the responsiveness of patients to serotonin and norepinephrine reuptake inhibitor like milnacipran, or to identify those patients who may experience AEs strong enough to warrant discontinuation of treatment. Keywords: major depressive disorder, milnacipran, biomarkers, adverse effects, cytokinesHashimoto TSakurai DOda YHasegawa TKanahara NSasaki TKomatsu HTakahashi JOiwa TSekine YWatanabe HIyo MDove Medical Pressarticlemajor depressive disordermilnacipranbiomarkersadverse effectscytokinesNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss Issue 1, Pp 3031-3040 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	major depressive disorder milnacipran biomarkers adverse effects cytokines Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	major depressive disorder milnacipran biomarkers adverse effects cytokines Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Hashimoto T Sakurai D Oda Y Hasegawa T Kanahara N Sasaki T Komatsu H Takahashi J Oiwa T Sekine Y Watanabe H Iyo M Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
description	Tasuku Hashimoto,1,2 Daiji Sakurai,1 Yasunori Oda,1 Tadashi Hasegawa,3 Nobuhisa Kanahara,4 Tsuyoshi Sasaki,3 Hideki Komatsu,3,5 Junpei Takahashi,1,5 Takahiro Oiwa,6 Yoshimoto Sekine,4,5 Hiroyuki Watanabe,1 Masaomi Iyo1,3 1Department of Psychiatry, Chiba University Graduate School of Medicine, 2Sodegaura Satsukidai Hospital, 3Department of Psychiatry, Chiba University Hospital, 4Division of Medical Treatment and Rehabilitation, Centre for Forensic Mental Health, Chiba University, 5Choshi Kokoro Clinic, 6Mobara Shinkeika Hospital, Chiba, Japan Background: We assessed the effect of switching patients with major depressive disorder to milnacipran following an initial selective serotonin reuptake inhibitor treatment failure, and explored potential biomarkers in their blood.Methods: We conducted a prospective, open-label, 24-week trial. Depression was assessed with the 17-item Hamilton Depression Rating Scale. Patients showing a ≥50% reduction in Hamilton Depression Rating Scale scores from baseline to final visit were considered responders. Regarding adverse effects (AEs), moderate-to-severe AEs were specifically identified as effects that required any medical treatment or that induced treatment withdrawals. We also measured blood levels of various molecules including inflammatory cytokines.Results: Of the 30 participants who enrolled, 17 completed this study. The responder rate was 30% (n=10). Baseline serum levels of interleukin-6 (Z=-2.155; P=0.031) and interleukin-8 (Z=-2.616; P=0.009) were significantly higher when moderate-to-severe AEs were present (n=13 patients with moderate-to-severe AEs). Serum levels of macrophage inflammatory protein-1β showed a significant continuous decrease from the baseline level (Friedman’s test: χ2=23.9, df=4, P<0.001) only in non-responders.Conclusion: These results demonstrate that serum levels of interleukin-6, interleukin-8, and macrophage inflammatory protein-1β as potential blood biomarkers could be utilized to identify the responsiveness of patients to serotonin and norepinephrine reuptake inhibitor like milnacipran, or to identify those patients who may experience AEs strong enough to warrant discontinuation of treatment. Keywords: major depressive disorder, milnacipran, biomarkers, adverse effects, cytokines
format	article
author	Hashimoto T Sakurai D Oda Y Hasegawa T Kanahara N Sasaki T Komatsu H Takahashi J Oiwa T Sekine Y Watanabe H Iyo M
author_facet	Hashimoto T Sakurai D Oda Y Hasegawa T Kanahara N Sasaki T Komatsu H Takahashi J Oiwa T Sekine Y Watanabe H Iyo M
author_sort	Hashimoto T
title	Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
title_short	Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
title_full	Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
title_fullStr	Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
title_full_unstemmed	Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
title_sort	milnacipran treatment and potential biomarkers in depressed patients following an initial ssri treatment failure: a prospective, open-label, 24-week study
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/4f49e3d6e16448a5b0101b6cdf3d5734
work_keys_str_mv	AT hashimotot milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT sakuraid milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT oday milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT hasegawat milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT kanaharan milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT sasakit milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT komatsuh milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT takahashij milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT oiwat milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT sekiney milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT watanabeh milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy AT iyom milnaciprantreatmentandpotentialbiomarkersindepressedpatientsfollowinganinitialssritreatmentfailureaprospectiveopenlabel24weekstudy
_version_	1718403926993141760

Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study

Ejemplares similares